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Abstract
In the paramyxovirus cell entry process, receptor binding triggers conformational changes in the fusion protein (F) leading
to viral and cellular membrane fusion. Peptides derived from C-terminal heptad repeat (HRC) regions in F have been shown
to inhibit fusion by preventing formation of the fusogenic six-helix bundle. We recently showed that the addition of a
cholesterol group to HRC peptides active against Nipah virus targets these peptides to the membrane where fusion occurs,
dramatically increasing their antiviral effect. In this work, we report that unlike the untagged HRC peptides, which bind to
the postulated extended intermediate state bridging the viral and cell membranes, the cholesterol tagged HRC-derived
peptides interact with F before the fusion peptide inserts into the target cell membrane, thus capturing an earlier stage in
the F-activation process. Furthermore, we show that cholesterol tagging renders these peptides active in vivo: the
cholesterol-tagged peptides cross the blood brain barrier, and effectively prevent and treat in an established animal model
what would otherwise be fatal Nipah virus encephalitis. The in vivo efficacy of cholesterol-tagged peptides, and in particular
their ability to penetrate the CNS, suggests that they are promising candidates for the prevention or therapy of infection by
Nipah and other lethal paramyxoviruses.
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Introduction
Fusion of enveloped viruses with the host cell is a key step in
viral infectivity. The fusion process during viral entry is driven by
specialized proteins that undergo an series of conformational
changes to bring the viral and host membranes together and
promote formation of a fusion pore (reviewed in [1]). For
paramyxoviruses — a family that includes a number of important
human pathogens — the steps in this process have been explored
over the last few years [2,3,4,5,6,7,8,9,10,11,12,13]. Each step,
from the interaction of the receptor-binding protein with its
receptor and the subsequent triggering of the fusion protein, to the
conformational changes in the fusion protein that lead to fusion
readiness, and the refolding of the fusion protein that drives
membrane merger, are potential targets for antiviral compounds.
Conversely, the use of compounds that block specific stages of the
entry process helps dissect the mechanism of entry.
NiV and Hendra (HeV) viruses are emerging zoonotic
paramyxoviruses [14] that are lethal to humans. HeV virus
infections currently pose a serious threat to livestock in Australia,
where sporadic and deadly transmission to humans has occurred,
with the potential for broader dissemination [15,16,17]. NiV
causes fatal encephalitis in up to 70% of human cases, and causes
seasonal outbreaks in Asia [18,19], with person-to-person
transmission now becoming a primary mode of spread
[20,21,22,23]. In addition to acute infection, these viruses cause
asymptomatic infection in up to 60% of exposed people, and may
lead to late-onset disease or relapse of encephalitis years after
initial infection [24], as well as persistent or delayed neurological
sequelae. No antiviral therapies or vaccines yet exist for HeV or
NiV. Other viruses belonging to the paramyxovirus family,
particularly respiratory syncytial virus (RSV) and the human
parainfluenza viruses types 1, 2, and 3 (HPIV1, 2, 3) [25,26], cause
the majority of childhood croup, bronchiolitis, and pneumonia
[27], contributing significantly to global disease and mortality,
while measles virus, despite the vaccine, continues to be an
important global agent of respiratory and neurologic disease [28].
All paramyxoviruses possess two envelope glycoproteins directly
involved in viral entry and pathogenesis: a fusion protein (F) and a
receptor-binding protein (HN for the parainfluenza viruses, H for
measles, or G for HeV and NiV). The paramyxovirus F proteins
belong to the group of ‘‘class I’’ fusion proteins [29,30], which also
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includes the HIV-1 gp41 fusion protein. The F protein is
synthesized as a precursor protein that is proteolytically processed
postranslationally to form a trimer of disulfide-linked heterodi-
mers. This cleavage event places the fusion peptide at the N-
terminus of the F1 subunit of the mature F protein, and is essential
for membrane fusion activity. For those viruses that fuse with cell
membranes at the cell surface, like HPIV, HeV, and NiV, the
receptor-binding protein binds to cellular surface receptors, brings
the viral envelope in proximity to the plasma membrane, and
activates the viral F protein to undergo the required conforma-
tional changes leading to fusion. Receptor-ligand interaction is
required for the F protein to undergo the series of steps that lead to
fusion [7,9,31]. It is generally thought that this activation requires
prior cleavage of the precursor F.
Peptides derived from the N-terminus heptad repeat (HRN) and
the C-terminus heptad repeat (HRC) regions of paramyxovirus
fusion (F) proteins can interact with fusion intermediates of F
[32,33,34,35,36,37]. In particular, peptides from the HRC regions
of a number of paramyxoviruses, including Sendai, measles, NDV,
RSV, SV5, HeV, and NiV can inhibit the infectivity of the
homologous virus [32,33,34,38,39,40,41,42]. We have shown that
peptides derived from the HRC of HPIV3 F are effective
inhibitors of both HPIV3 and henipavirus infection [13,42], and
that the efficacy of inhibition depends on both the strength of
interaction of the peptide with the target fusion protein and the
time window of access to the target sequence. By adding a
cholesterol group to an HPIV3 HRC-derived peptide, and thus
targeting the peptide to the membrane where fusion occurs, the
peptide becomes a highly effective inhibitor [43].
The current paradigm for the mechanism of HR-derived
peptide action proposes that HRC peptides bind to the postulated
extended intermediate state, after the fusion peptide has inserted
into the target membrane, and prevent the transition to the post-
fusion conformation [5,44,45]. Accordingly, peptides with greater
affinity for the intermediate state are better inhibitors. This has led
us (see below) and others to use structure-based design to improve
inhibitor potency. However, once fusion has proceeded past the
extended intermediate stage of F, peptide inhibitors are ineffective.
We have therefore proposed that the design of more effective
HRC peptide inhibitors should also aim at enhancing access and
association of inhibitor with the intermediate-stage fusion protein,
either by increasing the concentration of inhibitor at the location
of receptor binding, or by targeting an earlier stage of F-activation
[13]. Here, we report that the cholesterol-tagged HRC-derived
peptides interact with the F protein before the fusion peptide
inserts into the target membrane in the extended intermediate
state, thereby targeting and capturing an earlier stage in the F-
activation process than do the corresponding untagged peptides.
The stage of F-activation that is targeted by these peptides is
dependent upon HN-receptor interaction, but occurs prior to the
insertion of the fusion peptide into the target cell membrane.
These findings contrast with the existing paradigm that HR-
derived peptides cannot bind to F before F activation and insertion
into the target membrane [13,45,46,47]. In agreement with our
hypothesis, these peptides are potent antiviral compounds in vivo,
that accumulate in the CNS and effectively treat NiV encephalitis
in an established animal model.
Results
Design of improved HRC inhibitors
We addressed the design of improved HPIV3/NiV inhibitors in
four steps: (i) analysis of the crystal structure of the heterotypic
6HB complex; (ii) design of mutations aimed at improving
interhelical interaction; (iii) biophysical studies to prove that the
designed mutations yield 6HB with increased thermodynamic
stability, and (iv) combine the stability-enhancing mutations with
cholesterol conjugation. While steps (i)-(iii) were aimed at
decreasing the koff of the inhibitor-F complex, step (iv) was aimed
at increasing the kon for complex formation, and the two strategies
were expected to be additive, if not synergistic.
Crystal structure of the chimeric N42NiV/HeV(L6)C32HPIV3
complex: We previously showed that peptides corresponding to
the HRC region of human parainfluenza virus type 3 (HPIV3) are
better inhibitors of the heterologous paramyxoviruses Nipah (NiV)
or Hendra (HeV) than those derived from the HRC regions of
NiV or HeV themselves [42,48]. HPIV3 HRC peptides act by
binding to the F HRN coiled coil, disrupting postfusion six-helix
bundle (6HB) formation and blocking viral entry. The basis for this
phenomenon lies in the greater stability of the interaction between
the heterologous HRN-HRC pair (NiV-HPIV3) compared to the
homologous pair (NiV-NiV) [48]. To explain the greater stability
of the heterologous pair, we expanded on our previous residue-by
residue evaluation of the HRN-HRC interaction, and studied this
interaction in atomic detail. Based on the published crystal
structures of the HeV and NiV F six-helix bundles [49], we
designed and constructed a soluble polypeptide corresponding to
the chimeric fusion core (called N42NiV/HeV(L6)C32HPIV3), and
consisting of the NiV/HeV HRN N42 and HPIV3 C32 peptides
connected via a short peptide linker (Figure 1B); we deleted the first
proline residue in the HPIV3 HRC sequence in order to facilitate
crystallographic studies.
The crystal structure of N42NiV/HeV(L6)C32HPIV3 was solved by
molecular replacement (Table 1). The final 1.80-A˚ 2Fo – Fc
electron density map reveals the positions of all the amino-acid
residues except 19 at the helix termini and in the linker region
(Figure 1A). The quality of the structure was verified with
simulated annealing omit maps and by PROCHECK [50]. All
protein residues occupy the most favored regions of the
Ramachandran plot.
Like the wild-type NiV/HeV F core structure, the chimeric
N42NiV/HeV(L6)C32HPIV3 construct folds into a six-helix bundle
Author Summary
Nipah (NiV) and Hendra (HeV) viruses are two lethal
emerging zoonotic paramyxoviruses. In addition to acute
infection, these viruses may lead to late-onset disease or
relapse of encephalitis years after initial infection, as well
as persistent or delayed neurological sequelae. We present
a new strategy to prevent and treat NiV/HeV infection that
may be broadly applicable for enveloped viral pathogens.
Enveloped viruses must fuse their membrane with the
target cell membrane in order to initiate infection, and
blocking this step can prevent or treat infection, as
clinically validated for HIV. For paramyxoviruses, however,
peptides that bind the viral fusion protein have been
shown to inhibit fusion in vitro, but not in vivo. The new
strategy that we present here opens the door to clinically
effective paramyxovirus fusion-inhibitory peptides. By
targeting fusion-inhibitory peptides to the target mem-
brane using a cholesterol tag, we capture an early stage in
the viral fusion-activation process, thus drastically enhanc-
ing the efficacy of these peptides at inhibiting viral entry.
Importantly, this strategy prevents and treats lethal Nipah
virus infection in vivo. Membrane targeting of antiviral
peptides thus offers a new approach to development of
highly effective peptide fusion antivirals against important
human pathogens.
Antivirals Targeting a Fusion Protein Intermediate
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composed of three helical hairpins, each consisting of an N42 helix
paired with an antiparallel C32 helix (Figure 1). At the center of
the bundle, the side chains at the heptad a and d positions of the
NiV/HeV N42 coiled coil displayed typical ‘‘knobs-into-holes’’
packing interactions (Figure 1A). Three HPIV3 C32 helices wrap
in the reverse direction against the outside of the N42 coiled coil.
These C32 helices interact with the N42 helices through residues
in three highly conserved hydrophobic grooves on the surface of
the coiled-coil trimer (Figure 1C). In general, residues in the a and
d positions of the HPIV3 C32 helix pack against residues at the e
and g positions of the NiV/HeV N42 helices, while the peripheral
e and g side chains of C32 also participate in the hydrophobic
interactions (Figure 1B). The root mean square (rms) deviation
between all corresponding C atoms of the central N42 coiled coil
in the wild-type and chimeric six-helix bundles is 1.28 A˚. The
corresponding C atoms of the C32 helices in N42NiV/HeV
L6)C32HPIV3 can also be superimposed upon the wild-type
NiV/HeV counterpart with a rms deviation of 1.86 A˚. Thus,
the overall architecture and helix packing of the chimeric
construct are the same as that of the wild-type NiV/HeV F Core.
Although most of the helix-packing interface within the F core
structure involves hydrophobic interactions, interhelical hydrogen
Figure 1. Crystal structure of the chimeric six-helix bundle formed by the NiV/HeV HRN segment N42 and the HPIV3 HRC segment
C32. (A) Interacting cross-sectional layer of the N42NiV(L6)C32HPIV3 trimer. The 2Fo – Fc electron density map (contoured at 1.0sigma) is shown with
the refined molecular model. (B) Schematic representation of interfacial interactions between two adjacent N42NiV helices and a C32HPIV3 helix.
Packing interactions between residues at positions e and g of N42NiV and residues at positions d and a of C32HPIV3 are indicated by solid lines. (C)
Surface interaction properties of the N42NiV triple-stranded coiled coil with three C32HPIV3 chains drawn as an atomic model. The solvent-accessible
surface is colored according to the local electrostatic potential, ranging from +13 V in dark blue (most positive) to –10.3 V in deep red (most
negative). The positions of Ala463, Gln479 and Lys480 (colored in green) in C32HPIV3 are shown.
doi:10.1371/journal.ppat.1001168.g001
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bonds and salt bridges are uniformly distributed along the
hydrophobic contacts. In the chimeric structure, a cluster of polar
residues, including Ser153, Thr154, Asn155 of HeV/NiV N42,
and Arg476, Ser477, Asn478 of HPIV3 C32 (Figure 1A), is
involved in an intricate network of interhelical hydrogen bonds.
These favorable van der Waals and polar interactions in the
chimeric 6HB impart strong helical character and binding energy
to the HPIV3 HRC peptide for binding to the trimeric coiled coil
of HeV/NiV F, as predicted by a dominant-negative mode of
inhibition. Our results provide strong evidence that interhelical
packing interactions in the F ectodomain core are important
determinants of the stability of HRN-HRC interaction, and thus
of peptide inhibitor activity.
Design of peptides with improved interhelical packing: Based on
the above data, we sought to identify amino acid changes that
would increase heterotypic binding of the inhibitor to the HeV/
NiV coiled coil, while not perturbing, or possibly improving, its
homotypic binding to the HPIV3 coiled coil. First, the crystal
structures of the homo- and heterotypic six-helix bundles revealed
that HPIV3 Ala463 at a d position packs against Val169 of the
NiV coiled coil, while the corresponding NiV Met463 side chain
makes prominent contacts with hydrophobic grooves on the
surface of the coiled coil. Therefore in the HPIV3 HRC peptide
inhibitor, we substituted Ala463 with isoleucine, a preferred
residue in the d position and not prone to oxidation as methionine,
to strengthen its packing interactions with both HPIV3 and NiV/
HeV F.
Second, we considered the two residues at position 479–480,
Gln479-Lys480 in HPIV3 and Lys479-Ile480 in HeV/NiV, and
reasoned that introducing the 479–480 HeV/NiV residues in the
inhibitor to replace the corresponding HPIV3 residues would
result in several advantages: (i) The NiV Ile480 residue at a g
position is involved in the interhelix interaction with NiV Ser150,
while Lys480 in HPIV3 is not involved in a similar interaction.
Therefore substitution of Lys480 (HPIV3) with Ile480 (NiV) would
provide improved binding to the HeV/NiV coiled coil, and might
simultaneously improve binding to the HPIV3 coiled coil by
maintaining the hydrophobic packing of the methylene groups of
Lys480, while removing its buried charged and polar atoms; (ii)
NiV Lys479 at a f position forms an intra-helical hydrogen bond
with NiV Glu476, but this H-bond is not observed between the
HPIV3 Gln479 and Arg476 residues. Substitution of Gln479
(HPIV3) with Lys479 (NiV) therefore would not cause loss of an
interaction, while it would enhance helicity of the inhibitor. This
should increase the binding affinity for both HPIV3 and HeV/
NiV by decreasing the entropy penalty for folding; (iii) Exchanging
the HPIV3 Gln-Lys pair with the NiV Lys-Ile pair would not
change the local electrostatic balance.
Biophysical studies of mutated 6HBs: To directly test whether
these mutations enhance stability of the 6HB, we mutated the
Ala463, Gln479 and Lys480 residues of the C32 segment in the
recombinant N42(L6)C32 model of the homotypic and chimeric F
6HBs [48]. We compared the stability of the 6HBs formed
between HRN-peptides (both HPIV3 and NiV) and the previously
described HRC peptides [48] with the 6HBs formed with the new
VIKI mutant (containing the mutations E459V, A463I, Q479K,
K480I). Note that all peptides bear the Glu459-to-Val mutation
that we previously identified as enhancing HRN-HRC interaction
and potency [48].
Circular dichroism (CD) spectroscopy indicated that the
recombinant proteins (N42HPIV3(L6)C32HPIV3-VIKI, and N42NiV
(L6)C32HPIV3-VIKI) were well folded and contained .90% helical
structure at 4uC in 50 mM Tris-HCl (pH 8.0) and 150 mM NaCl
(TBS) (Table 2, Figure 2A). Analytical ultracentrifugation
experiments indicated that each protein forms a discrete trimer
over a concentration range from 30 to 300 uM (Table 2,
Figure 2C). The thermal stability of the homotypic and chimeric
N42(L6)C32 6HB for the panel of different peptides was assessed
using CD by monitoring the ellipticity at 222 nm as a function of
temperature at 50 mM protein concentration in TBS (pH 8.0).
N42HPIV3(L6)C32HPIV3-VIKI, and N42NiV(L6)C32HPIV3-VIKI have
thermal stabilities that exceed 100uC (Table 2, Figure 2B). In the
presence of the denaturant guanidine hydrochloride (GuHCl) at 3
M concentration, N42NiV(L6)C32HPIV3-VIKI peptides unfold
cooperatively, with an apparent melting temperature (Tm) of
78uC (Figure 2B), compared to a Tm of 72uC for the parent
N42NiV(L6)C32HPIV3-V with the Glu459-to-Val mutation and to a
Tm of 67uC for the original HPIV3 sequence N42NiV(L6)C32HPIV3
(Table 2, [48]). On the other hand, N42HPIV3(L6)C32HPIV3-V
forms an unusually stable helical structure, with an apparent Tm of
.95uC in the presence of 5 M GuHCl [48] even without the Ile-
Lys-Ile mutations, and N42HPIV3(L6)C32HPIV3-VIKI has an
apparent Tm of .100uC under the same conditions [48]
(Table 2). Taken together, these results indicate that the Ile-Lys-
Ile substitutions in the VIKI mutant yield a more stable interaction
with both (NiV and HPIV3) HRNs compared to the previously
described peptide.
Combining stability-enhancing mutations with cholesterol
conjugation: We have previously shown that addition of a
cholesterol moiety to the C-terminus of a 36-amino acid peptide
corresponding to the HRC region of HPIV3 F (V-chol, Table 3)
improves the antiviral activity by 2 logs [43]. The cholesterol
conjugation increases the concentration of the inhibitor in
Table 1. Crystallographic data and refinement statistics.
Data collection
Resolution (A˚) 67.1–1.80
No. of unique reflections 20,844
Redundancy 5.4 (5.1)*
Completeness (%) 92.5 (75.3)
Rmerge (%) 5.9
I/sI) 13.7 (2.6)
Space group P212121
Unit-cell parameter a = 32.4 A˚, b = 54.1 A˚, c = 134.1 A˚
No. of molecules in AU 3
Solvent content (%) 43.5
Refinement
Resolution (A˚) 67.1–1.80
No. of reflections 20,844
No. of protein atoms 1,738
No. of water molecules 156
No. of citrate ion 1
No. of t-butanol 2
Rcryst/Rfree (%) 19.4/24.2
Average B-factor (A˚2) 32.2
rms deviations
Bond lengths (A˚) 0.011
Bond angles (u) 1.2
B values (A˚2) 5.8
*The highest resolution shell (1.86–1.80 A˚) is shown in parenthesis.
doi:10.1371/journal.ppat.1001168.t001
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cholesterol-rich lipid rafts, where viral fusion is triggered after the
initial attachment of the virus to the host cell [43,51,52]. We
conjugated a cholesterol group to the VIKI mutant. In doing so,
we also introduced a small spacer made of 4 units of polyethylene
glycol (PEG4), a well-known solubilizing moiety, between the
peptide and the cholesterol moiety, to improve the physicochem-
ical properties of the conjugated peptide (VIKI-PEG4-chol,
Table 3). We reasoned that a flexible spacer between the
membrane-bound cholesterol moiety and the cysteine residue to
which it is attached might also reduce any steric strain resulting
from the need of simultaneous, oriented binding of the inhibitor to
the membrane and the HRN moiety of F – the relative geometry
of which is expected to change during the progress of fusion.
Accordingly, we found that the PEG spacer not only considerably
improves peptide solubility in acqueous media, but also enhances
activity.
The sequence-optimized, cholesterol-tagged peptide is
the most potent inhibitor of HPIV3 infectivity
The inhibitory activity of V-chol, V-PEG4-chol, and VIKI-
PEG4-chol (Table 3) against HPIV3 was assessed in a plaque
reduction assay (Figure 3). The peptides containing the PEG4
spacer both performed better than the original peptide. While for
the cholesterol-tagged peptide with no spacer the IC50 value is
,10 nM, for PEG4-containing peptides the IC50 value decreases
to,0.7 nM (V-PEG4-chol) and,0.3 nM (VIKI-PEG4-chol). The
VIKI peptide outperformed the other peptides over a wide range
of concentrations. Taken together, the data in Figure 3 indicate
that (i) the effects of cholesterol and of the amino acid substitutions
are additive, and (ii) addition of a PEG spacer between the C-
terminal cysteine and the cholesterol group independently and
further improves the overall efficacy of the entry inhibitor against
HPIV3.
The sequence-optimized, cholesterol-tagged peptide
inhibits viral infection in human airway epithelium
For clinical utility, the ability of an antiviral agent to prevent
multiple rounds of infection is key. We recently established that a
human airway epithelium (HAE) model closely reflects the in vivo
behavior of a panel of HPIV3 variants [53]. The HAE model was
previously used to characterize the cell specificity of respiratory
syncytial virus [54] and HPIV3 [55], a study which confirmed that
the model replicates those paramyxovirus-HAE interactions that
occur in the human lung. We also recently employed this system to
test a sialidase-based inhibitor, and showed a direct correlation
between the HAE and in vivo results [56]. We therefore
hypothesized that peptide efficacy in this ex vivo model would
correlate with in vivo efficacy.
We assessed the effect of the cholesterol tagged peptides on viral
infection in HAE (Figure 4). The pseudostratified epithelium was
infected at the apical surface with wt HPIV3 in the presence of
1000 nM of each peptide. After a 90 minute adsorption period,
the liquid from the apical surface, containing virus and peptide,
was aspirated, and the titer of virus emerging from the apical
surface was measured at 2, 3, 5, and 7 days post-infection [53].
Figure 4 shows that at two days post-infection, neither the V-chol
nor the V-PEG4-chol peptide reduced the viral titer; the titer in
the presence of those peptides is the same as for untreated control
wells. At the same time point, after a single initial dose of the
VIKI-PEG4-chol peptide, the titer was reduced by 80%. Even at 5
days after infection, the single initial dose of VIKI-PEG4-chol
peptide reduced viral titer by ,50%. Thus, a single dose of the
VIKI-PEG4-chol peptide blunted the viral titer in HAE over
several days; only after 7 days we observe a major decline in the
inhibitory effect. The viral titers at each time point are presented
in table S1. These results provided support for the efficacy of
tagged peptides in the natural host and will lead to future
experiments in an animal model.
The sequence-optimized, cholesterol-tagged peptide is
the most potent inhibitor of both HPIV3 and NiV fusion
While in HAE the VIKI-PEG4-chol peptide inhibition of viral
titer was far superior to the other two cholesterol-tagged peptides
(Figure 4), all three peptides completely inhibited infection in
monolayer culture (Figure 3) at the concentration of peptide that
was used in the HAE (1000 nM). To address this difference, we
turned to a quantitative fusion assay based on beta-galactosidase
complementation, that we have found to accurately reflect the
HAE and in vivo results in the assessment of inhibitors [12,42,53].
For the experiment shown in Figure 5, fusion mediated by HPIV3
or NIV in the presence or absence of inhibitory peptides was
measured after incubation at 37uC for 4 hours. The peptides were
present during the entire fusion process, allowing them to act at
the stages of triggering/activation of the fusion protein, or during
subsequent fusion.
Figure 5 shows the percent inhibition of fusion mediated by
either HPIV3 F coexpressed with HPIV3 HN (Figure 5A) or NiV
F coexpressed with NiV G (Figure 5B), in the presence of
increasing concentrations of V-chol peptide (squares), V-PEG4-
chol peptide (triangles) or VIKI-PEG4-chol peptide (circles).
Fusion between cells expressing viral envelope glycoproteins
(HPIV3 HN/F or NiV G/F) and the alpha beta-gal subunit and
cells expressing the omega beta-gal subunit was quantitated.
Fusion mediated by the HPIV3 glycoproteins F and HN was
inhibited only by the VIKI-PEG4-chol peptide, with an IC50 value
of ,30 nM and maximal inhibition at 50 nM (Figure 5A). The
other two peptides did not inhibit fusion even at the highest
concentration used here (1000 nM).
While cell fusion mediated by NiV F coexpressed NiV G was
inhibited by all three peptides, at each concentration, the VIKI-
Table 2. Biophysical data of mutant N42(L6)C32 polypeptides.
–[q]222 nm (deg cm
2 dmol–1) Tm (uC) Tm
3M GuHCl* (uC) Tm
5M GuHCl* (uC) Mobs/Mcalc
^
N42NiV(L6)C32HPIV3-V 34,600 .100 72 ,0 2.9
N42NiV(L6)C32HPIV3-V/IKI 32,000 .100 78 ,0 3.0
N42HPIV3(L6)C32HPIV3-V 32,600 .100 .100 .95 3.0
N42HPIV3(L6)C32HPIV3-V/IKI 32,800 .100 .100 .100 3.1
*Tm
GuHCl denotes the apparent melting temperature in 3 or 5 M GuHCl. All CD scans and melts were performed on 50 mM protein solutions in TBS (pH 8.0).
^Mobs/Mcalc is the apparent molecular mass determined from sedimentation equilibrium data divided by the calculated molecular mass of a monomer.
doi:10.1371/journal.ppat.1001168.t002
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PEG4-chol peptide was more inhibitory than the other two
peptides (Figure 5B). These results for both HPIV3 and NiV led us
to further explore the basis for the VIKI-PEG4-chol peptide’s
efficacy.
The sequence-optimized, cholesterol-tagged peptide
interacts with F prior to the fusion peptide insertion into
the target membrane
We hypothesized that the IKI mutations in the VIKI-PEG4-
chol peptide might affect the peptide’s mechanism of action. To
investigate the point in the fusion process at which VIKI-PEG4-
chol acts, we used an assay that we previously designed to
distinguish between different states of F activation [7,12]. This
assay allowed us to address that the VIKI-PEG4-chol and the
other two peptides target different states of F activation.
To determine whether the peptides interact with F before
insertion of the fusion peptide into the cell membrane, we first
used a cleavage site mutant F (F-csm) that does not expose the
fusion peptide, and therefore cannot mediate membrane merger
[11,57], and an HPIV3 HN (T193A HN) that possesses high
binding avidity and therefore dissociates from its receptor only in
the presence of zanamivir [12]. The F-csm permits assessment of
the stages the fusion sequence prior to fusion peptide membrane
insertion, and the T193A HN removes the variable of receptor
dissociation during the experiment, allowing us to focus on
potential interactions of peptide with F prior to membrane
insertion.
To compare the stage of peptide action between the VIKI-
PEG4-chol and the other two peptides (Figure 6), cells co-
expressing HPIV3 F-csm and T193A HPIV3 HN were allowed to
bind erythrocytes (RBCs) at 4uC. The cells were then washed and
medium containing V-chol, V-PEG4-chol, VIKI-PEG4-chol (at a
concentration of 1 uM), or no peptide, was added. The cells were
transferred to 37uC to allow F-activation to occur, and at the
indicated time points zanamivir was added to interfere with HN-
receptor interaction [7,8,9,10,58,59]. We determined the amount
of target RBCs that (a) were released into the medium by
zanamivir addition (yellow), (b) were bound but had not fused
(green), or (c) had undergone fusion (blue). As expected, no fusion
was mediated by F-csm. In the absence of peptide (Figure 6A) all
of the RBCs were released by zanamivir, indicating that binding is
completely HN-dependent at all the time points. However, for all
the cholesterol tagged peptides, there is a progressive increase in
the quantity of RBCs that are not detached by zanamivir, and are
thus irreversibly bound. This result indicates that in the presence
of the cholesterol-tagged peptides, RBCs are retained in an HN-
independent manner, suggesting that the peptide-F interaction
causes the RBCs to remain attached to the HN/F-expressing cells.
This effect is observed only with the C-terminally cholesterol-
tagged peptides; N-terminally tagged or untagged peptides show
no RBC retention (Figure S1).
Two potential interpretations of these findings are that: (1) the
cholesterol-tagged peptides, which are anchored in the target RBC
membrane, interact with the uncleaved F molecule and form a
bridge between the HN/F-expressing target cell membrane and
the RBC membrane, or (2) the peptide is interacting with the
Figure 2. Engineered mutations enhance the interactions of
two hydrophobic heptad-repeat (HRN and HRC) regions in NiV
and HPIV3 F. Ala463-to-Ile, Gln479-to-Lys and Lys480-to-Ile mutations
(in the HPIV3 F HRC region) stabilize the heterotypic six-helix bundle
structure formed by the recombinant N42NiV(L6)C32HPIV3-V model. (A)
Circular dichroism (CD) spectrum of N42NiV(L6)C32HPIV3-VIKI (50 uM) in
TBS (pH 8.0) at 4uC. (B) Thermal melts of N42NiV(L6)C32HPIV3-VIKI
monitored by CD at 222 nm at 50 uM protein concentration in TBS
(pH 8.0) in the presence (open circles) and absence (filled circles) of 3 M
GuHCl, a chemical denaturant. (C) Representative sedimentation
equilibrium data (19 krpm) of N42NiV(L6)C32HPIV3-VIKI collected at 20uC
in TBS (pH 8.0) at ,30 uM protein concentration. The natural logarithm
of the absorbance at 273 nm is plotted against the square of the radial
position. The random distributions of the residuals indicate that the
data fit well to an ideal single-species model. The slope of the plotted
data indicates that N42NiV(L6)C32HPIV3-VIKI is a trimer.
doi:10.1371/journal.ppat.1001168.g002
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uncleaved F molecule and thereby stabilizing F binding to an
unknown ‘‘F receptor’’ [46]. We disfavor this second possibility
since we find that only insertion of peptide into the RBC (target)
cell membrane, and not into the HN/F-expressing membrane,
leads to the peptide-F interaction (Figure S2).
The diagram in Figure 7 shows our proposed mechanism for the
interaction of cholesterol-tagged peptides with the uncleaved F
molecule and the formation of a bridge between the HN/F-
expressing cell and the target membrane. Panel A schematically
represents native, cleaved F after activation and insertion of the
fusion peptides into the target membrane. In panel B, F is
uncleaved and there is no fusion peptide insertion and therefore no
irreversible attachment to the target membrane. In panel C, the
uncleaved F is schematically represented as attached to the target
membrane via the cholesterol-tagged peptide’s interaction with
both the target membrane and the uncleaved F. We postulate that
for this to occur, the uncleaved F must have undergone
conformational change to expose the HRN regions, and the
cholesterol-tagged peptide then captures this transitional interme-
diate.
While all three cholesterol peptides mediate HN-independent
attachment, there are clear differences between them: VIKI-
PEG4-chol promotes rapid irreversible binding, V-chol is the
slowest to promote irreversible binding (Figure 6B) and V-PEG4-
chol achieved irreversible retention in an intermediate time
(Figure 6C). Importantly, the ability of each peptide to promote
RBC retention is well correlated with the inhibitory efficacy of
each peptide (Figure 4 and 5).
To confirm that the results obtained with F-csm are valid also
for wild-type F, we repeated the assay described in Figure 6 using
native F and a range of temperatures, including temperatures (0o,
10o, 15o) at which we know from previous experiments that F-
activation is negligible [12]. In this experiment (Figure 8), cells co-
expressing HPIV3 F and T193A HPIV3 HN were allowed to bind
erythrocytes (RBCs) at 4uC. The cells were then washed and
medium containing VIKI-PEG4-chol or untagged peptide (at a
concentration of 10 uM), or no peptide, was added. The cells were
transferred to the indicated temperatures to allow F-activation to
occur, and after 60 minutes, zanamivir was added to interfere with
HN-receptor interaction [7,8,9,10,58,59]. We then determined the
amount of target RBCs that were either released into the medium,
irreversibly bound (not released by zanamivir), or fused, as for the
experiment in Figure 6. Figure 8 shows the % of RBCs that were
irreversibly bound at each temperature, in the presence of VIKI-
PEG4-chol (red bars), untagged VIKI peptide (green bars) or no
peptide (blue bars). In the absence of peptide, at every temperature
all or almost all of the RBCs were either fused or released by
zanamivir, indicating a lack of fusion peptide insertion into the
target membrane. In the presence of VIKI-PEG4-chol however, a
remarkable 20% of RBCs are irreversibly bound at 10o, a
temperature too cold for fusion peptide insertion [12,46]. At 15o,
65% of RBCs are irreversibly bound in the presence of VIKI-
PEG4-chol. At this temperature, 20% of RBCs are irreversibly
bound in the presence of the untagged VIKI peptide, correspond-
ing to the extent of inhibition by the untagged peptide after fusion
peptide insertion into the target membrane. The difference
Table 3. Comparison of properties of cholesterol-tagged peptides.
Short name PEG linker HPIV3 F derived HRC sequence IC50 (nM)
NiV HPIV3
infection* fusion infection fusion
V-chol NO 449-VALDPIDISIVLNKAKSDLEESKEWIRRSNQKLDSI-484 ,0.02 ,300 ,10.0 .1000
V-PEG4-chol YES 449-VALDPIDISIVLNKAKSDLEESKEWIRRSNQKLDSI-484 ,0.02 ,80.0 ,0.70 .1000
VIKI-PEG4-chol YES 449-VALDPIDISIVLNK I KSDLEESKEWIRRSNK I LDSI-484 ,0.02 ,5.0 ,0.30 ,30.0
*PSEUDOTYPE ASSAY.
doi:10.1371/journal.ppat.1001168.t003
Figure 3. Inhibition of HPIV3 infection by HPIV3 F HRC cholesterol-tagged peptides. CV1 cell monolayers were infected with wild type
HPIV3 at a multiplicity of infection (m.o.i.) of 6.761024 in the presence of increasing concentrations of the VIKI-PEG4-chol (circle), V-PEG4-chol
(triangle) or V-chol (square) peptides. After a 90-min incubation at 37uC, cells were overlaid with methylcellulose, and plaques were stained and
counted after 24 h. The percent inhibition of viral entry (compared to results for control cells infected in the absence of inhibitors) is shown as a
function of the (log-scale) concentration of peptide. Data points are means (6 SD) for triplicate samples. These data are representative of results from
three to five experiments.
doi:10.1371/journal.ppat.1001168.g003
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between the 65% retention by VIKI-PEG4-chol and the 20%
retention by the corresponding untagged peptide represents the
portion of the RBCs that are retained by the tagged peptide prior
to fusion peptide insertion. At 25o, both peptides inhibit fusion to
the same degree, and the experiment can no longer distinguish
between peptide interaction that occurs before or after fusion
protein insertion.
Since the experiment at 15o is most indicative of the interaction
of the cholesterol-tagged peptide with native F protein at an early
stage of activation, we carried out a time course experiment at this
temperature (Figure 9). In this experiment, cells co-expressing
wild-type cleaved F and HN were allowed to bind RBCs at 4uC.
The cells were then washed and medium containing V-chol, V-
PEG4-chol, VIKI-PEG4-chol, V-untagged, VIKI-untagged (at a
concentration of 1uM), or no peptide, was added. The cells were
transferred to 15uC, and at the indicated time points zanamivir
was added. As expected, only minimal fusion was mediated at this
temperature at 5 or 15 minutes. In the absence of peptide (panel
A), most of the RBCs were released by zanamivir, indicating that
binding is completely HN-dependent at 5, 15 and 30 minutes. In
the presence of untagged peptides (panels B, C), the level of
irreversibly bound peptide correlates directly with the onset of
fusion, and represents inhibition of the progress of fusion once
fusion peptide insertion occurs. However, for all the cholesterol
tagged peptides (D, E, F), there is a progressive increase in the
quantity of RBCs that are not detached by zanamivir, and are thus
irreversibly bound, at times before fusion peptide insertion (15 and
30 minutes, compare to untagged peptide panels B, C). At 30
minutes, ,50% of RBCs are irreversibly bound in the presence of
chol-tagged peptides, although at this time point only ,20% have
inserted their fusion peptide (i.e., retained by untagged peptides.)
This result indicates that in the presence of the cholesterol-tagged
peptides, RBCs are retained in an HN-independent manner, with
the peptide-F interaction causing the RBCs to remain attached to
the HN/F-expressing cells at a stage before fusion peptide
insertion.
Overall, these results indicate that the C-terminally cholesterol-
tagged peptides can interact with F before the insertion of the
fusion peptide into the membrane, that the sequence-optimized
VIKI-PEG4-chol interacts better with this early stage of F, and
that this interaction is the basis for the peptide’s efficacy.
The sequence-optimized, cholesterol-tagged peptide
penetrates into the Central Nervous System
As a preliminary step towards testing VIKI-PEG4-chol in vivo,
we assessed its pharmacokinetics (PK) in cotton rats, a model for
HPIV3 infection [53,60], and golden hamsters, a model for NiV
infection [61,62,63]. We found that the peptide half-life is lower in
cotton rats than in golden hamsters, and we therefore conducted
further studies in golden hamsters. We specifically sought to
determine whether the peptide biodistribution extends to the CNS
— the target tissue of NiV. The biodistribution of VIKI-PEG4-
chol in golden hamsters after a single subcutaneous injection of
2 mg/kg is shown in Figure 10. We observed an increase of the
plasma peptide concentration to a peak of 800 nM after 8 hours
(Figure 10A). Importantly, the plasma concentration after
24 hours was still approximately 200 nM, i.e. 100-fold the in vitro
IC50 value for NiV [43] (see also Table 3). This indicated that a
single daily dose of peptide would be enough to maintain a
therapeutic dosage in vivo.
We found high concentrations of peptide also in the lung,
endothelium, and brain (Figure 10B), the organs that are
particularly relevant in the course of NiV infection. The peptide
concentration in the lung and endothelium peaks at 8 h, with
values of 120 nM and 170 nM, respectively, and slowly falls to
40 nM and 130 nM at 24 hours, values still considerably higher
than the in vitro IC50. As expected, the kinetics of accumulation of
the peptide in the brain is shifted with respect to the peak of
plasma concentration. The peptide is first detected at 8 h (34 nM)
and its brain concentration increases to 190 nM after 24 h.
The sequence-optimized, cholesterol-tagged peptide is
efficacious in vivo
We next evaluated the prophylactic and therapeutic efficacy of
VIKI-PEG4-chol. The peptide was administered to golden
hamsters intraperitoneally, either concurrently with virus infec-
tion, or with targeted post-exposure and prophylactic therapeutic
regimes. Based on the biodistribution study, the peptide dose was
2 mg/kg administered daily, to achieve a plasma concentration
$100x the in vitro IC50 throughout the 24 hours. Peptide
injections were administered to groups of 5 hamsters at 2 days
or 1 day before infection, concurrently with infection, and at 1, 2
or 4 days after infection. Injections were then repeated every day
for up to 14 days post-infection. The hamsters were challenged by
intraperitoneal inoculation of NiV, using 100x the LD50. The
infected hamsters were observed daily for clinical signs (prostra-
tion, neurological signs) and variations in temperature and weight.
All the untreated animals were euthanized within 7 days after
infection due to neurological disease (Figure 11).
Treatment of animals 2 days before challenge resulted in 100%
protection against disease for at least 21 days after infection
(Figure 11). One of the surviving animals died at 23 days after
infection (i.e. after 9 days without treatment) with neurological
disease of unknown cause. Treatment concurrent with infection
led to an 80% survival rate. Surprisingly, in light of the highly
lethal nature of this virus, even treatment 2 days after infection led
to survival of 40% of the animals. Of the animals treated 4 days
post-infection, the onset of the illness was greatly delayed with a
significantly extended lifespan, though only one of five animals
survived to 30 days. While some of the findings need to be clarified
with seroconversion and pathology studies, the overall picture is
Figure 4. VIKI-PEG4-chol peptide efficiently curtails multicycle
replication in HAE culture. HAE were infected with HPIV3 in the
presence of 1uM VIKI-PEG4-chol (circle), V-PEG4-chol (triangle) or V-chol
(square) peptide. After a 90 min incubation at 37uC, the inoculum was
removed and the HAE were incubated at 37uC. The virus released from
the apical surface was collected at the indicated time points. The
percent reduction in viral titer (compared to results from mock infected
samples) is shown as a function of time. Values represent means 6 SD
of 3 replicate samples. These data are representative of an experiment
repeated 3 times.
doi:10.1371/journal.ppat.1001168.g004
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clearly one of protection and effective therapy for this otherwise
lethal disease.
Discussion
Fusion between viral and cell membranes initiates infection and
is a key early step in the entry of enveloped viruses [3,44]. Peptides
derived from a number of viral fusion (F) proteins can inhibit
infection. For the paramyxoviruses in analogy to HIV, F-derived
peptides have been thought to interact with the fusion protein
intermediate that exists after activation of the pre-cleaved F
protein and the insertion of the fusion peptide into the target cell:
this extended intermediate bridges the viral and cell membranes,
and its refolding into a 6HB is a key driver for membrane fusion
[45]. Peptides that correspond to the HRC region of F are
believed to bind HRN domain of the extended intermediate and
prevent its refolding into a the 6HB. The data reported in this
manuscript however suggest that if HRC peptides are localized to
the cell membrane by a cholesterol tag, and are engineered to
interact more strongly with the HRN target domain, they become
capable of interacting with F prior to the insertion of the fusion
peptide into the target cell membrane. These peptides thus capture
an earlier stage in the F-activation process.
Which intermediate is the target of the sequence-
optimized, cholesterol tagged peptides?
It is generally assumed that in order to mediate fusion and viral
infectivity, the precursor (F0) protein must be cleaved into subunits
F1 and F2 during transit to the cell surface, with the fusion peptide
present at the F1 terminus but protected in the molecule’s interior
until activation. Our data however indicate that uncleaved F0 –
only upon receptor engagement of the receptor binding protein,
HN — undergoes conformational changes sufficient to expose the
HRN domain to inhibitors. The interaction between uncleaved F0
and cholesterol-tagged peptide inhibitors is sufficient to irreversibly
connect the viral and target cell membranes. We show this
interaction both for a F protein cleavage-site mutant, incapable of
fusion protein insertion, and for native, cleaved F protein at low
temperature.
While our results provide the first biological evidence for
conformational flexibility of an uncleaved precursor paramyxovi-
rus fusion protein, the reported crystal structure of the uncleaved
HPIV3 F appeared to be in a post-fusion state [57], suggesting that
possibly the uncleaved precursor had undergone activation.
Interestingly, similar conformational changes have been suggested
for the uncleaved precursor of the influenza precursor fusion
Figure 5. HPIV3 F HRC cholesterol-tagged peptides inhibit cell fusion mediated by HPIV3 HN/F and NiV G/F. HPIV3 HN/F (A) or NiV G/F
(B) co-expressing cells were allowed to fuse with sialic acid receptor-bearing cells (293T) in the presence of increasing concentrations of VIKI-PEG4-
chol (circle), V-PEG4-chol (triangle) or V-chol (square) peptide. After 4 hours, the amount of fusion was quantitated using a beta-galactosidase
complementation assay as described in Materials and Methods. The percent inhibition of fusion (compared to results for control cells not treated with
peptide) is shown as a function of the (log-scale) concentration of peptide. The values are means (6 SD) of results from three experiments.
doi:10.1371/journal.ppat.1001168.g005
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protein (HA0), which could be triggered to its irreversible pH-
induced conformational change, without membrane insertion
[64].
At 15o, all three cholesterol-tagged peptides bind to the early F
intermediate and stabilize the pre-insertion state (Figure 9 and
unpublished data). However at 37o, only the most efficient peptide
is able to stabilize the intermediate. The efficiency with which the
cholesterol-tagged inhibitors cause irreversible attachment is
directly correlated to their inhibitory potency. The VIKI-PEG4-
chol peptide, which interacts with the uncleaved, activated F
protein most effectively, was designed to bind more avidly to the
HRN, was shown by biophysical data to do so, and is the most
effective inhibitor of infection. It is therefore tempting to speculate
a causal connection between targeting an earlier intermediate
along the reaction coordinate and increased potency, via an
extended temporal window of opportunity. While more studies
will be necessary to understand the mechanism of action, it is
already clear at this stage that our design strategy is highly effective
in vivo, as shown in an animal model of lethal NiV infection.
NiV has emerged as an important new cause of fatal
encephalitis in humans. While the virus targets both the vascular
endothelium and neurons, human disease is dominated by severe
encephalitis in the acute phase, with severe brainstem involvement
in fatal cases [65]. Even after recovery from acute encephalitis,
NiV may persist in the central nervous system. During the late-
onset encephalitis form of disease, the virus is exclusively localized
to neurons.
For the henipaviruses, small animal models have been under
development in recent years. While tropism for the endothelium is
a hallmark of infection in both humans and animals, the various
animal models have different degrees of CNS involvement. The
animal model used in this study, the golden hamster, develops
CNS manifestations of disease similar to the human disease, while
other animal models, for example the cat [66], the ferret [67] or
the naturally infected pig [68] develop primarily respiratory
disease [61,66,67,69]. We contend that the CNS component is
essential to assess therapies that may be useful in human disease.
Several recent studies have raised the possibility of active or
passive immunoprotection for henipaviruses [62,63,70]. In the cat,
a subunit vaccine based on soluble glycoproteins protected the
animals from subsequent viral infection [66]. While active
immunization may be a useful strategy for livestock, it is unlikely
Figure 6. HPIV3 F HRC cholesterol-tagged peptides interact with uncleaved F: peptide-F interaction attaches HN/F-expressing cells
to receptor-bearing target cells. Monolayers of cells co-expressing HN and uncleaved (cleavage site mutant, csm) F were allowed to bind to
receptor-bearing RBCs at 4uC. Upon transfer to 37uC, media containing (A) no peptide, (B) 1 uM V-chol peptide, (C) 1 uM V-PEG4-chol peptide, or (D) 1
uM VIKI -PEG4-chol peptide were added. Zanamivir was added to block HN-receptor interaction at the indicated timepoints and RBCs that were
reversibly bound by HN-receptor interaction (yellow), irreversibly bound (green), or fused (blue) were quantified. The ordinate values are means (6
SD) of results from triplicate samples.
doi:10.1371/journal.ppat.1001168.g006
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that a broad human vaccine campaign for these pathogens is
feasible. Recently, in ferrets, passive immunotherapy with a
human monoclonal antibody produced partial protection when a
high dose of the antibody was injected IV at 10 hours post
infection with NiV [67]. However, in ferrets the NiV disease is
predominantly respiratory, with a neurological syndrome observed
only occasionally (2), and therefore to be effective in ferrets, a
therapy may not need to reach the CNS.
The peptide reported here localized effectively in the CNS, and
may offer protection in protected sites that are inaccessible to
antibodies or hydrophilic small molecules. For example, although
ribavirin inhibits NiV and HeV efficiently in vitro [71], it only
slightly decreased the mortality of NiV encephalitis [72]; this may
be explained by its failure to cross the blood-brain barrier. In
support of this notion, hamsters with measles encephalitis died
with ribavirin treatment if the route of injection was intraperito-
neal, while intracranial injection of ribavirin resulted in complete
protection [73]. Recently, two new nonhuman primate models
susceptible to Nipah virus infection have been described: Squirrel
Monkeys [74] and African Green Monkeys (13). Infection in these
primates is followed by the high death rates associated with acute
neurological and respiratory illness, closely resembling the disease
in humans. We plan to validate our candidate therapeutics in these
models as a key for further clinical development [74,75]. It should
Figure 7. Schematic illustration of the proposed mechanism of cholesterol-tagged peptides. The panels show the interaction of
cholesterol-tagged peptides with the uncleaved F molecule (B) and the formation of a bridge between the HN/F-expressing cell and the target
membrane (C). For comparison, native cleaved F is shown with the fusion peptide inserted into the target cell (A).
doi:10.1371/journal.ppat.1001168.g007
Figure 8. HPIV3 F HRC cholesterol-tagged peptides interact with native cleaved F: peptide-F interaction attaches HN/F-expressing
cells to receptor-bearing target cells at an early stage of F-activation. Monolayers of cells co-expressing HN and F were allowed to bind to
receptor-bearing RBCs at 4uC. Upon transfer to the indicated temperatures, media containing no peptide (blue bar), 10 uM VIKI -PEG4-chol (red bar),
or 10 uM VIKI-untagged peptide (green bar) were added. At 60 minutes, zanamivir was added to block HN-receptor interaction and RBCs that were
irreversibly bound were quantified. The values are means (6 SD) of results from triplicate samples.
doi:10.1371/journal.ppat.1001168.g008
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also be noted that the peptides described in the current work
inhibit the virus at a post-attachment stage, and are therefore
expected to act synergistically with agents, like the above described
antibody [67], that block viral attachment. Combination therapy is
now the mainstay for HIV and other viral diseases where multiple
therapeutic options are available.
While our animal studies focused on NiV, this antiviral strategy
is applicable to other enveloped viruses as well, including several
important pathogens. For example, the fact that the peptides are
equally effective on NiV and HeV in vitro (not surprising since the
HRN regions of the two viruses are identical) suggests that HeV
infection will also respond to these peptides in vivo. Moreover,
based upon our data indicating efficacy of VIKI-PEG4-chol
against the HPIV3 in the HAE model, we anticipate this approach
may lead to effective prevention and treatment of HPIV. Together
with respiratory syncytial virus (RSV) HPIV has a huge impact on
illness and hospitalization of young infants worldwide. No drugs or
vaccines are available for these two viruses, and development of
antiviral drugs has been a great challenge.
From the point of view of inhibitor design, we anticipate several
directions to further develop our HPIV3/henipavirus inhibitor.
First, the major effect that we observed from an apparently small
change — the introduction of a 4-unit PEG spacer between the C-
terminal cysteine of the peptide and the cholesterol moiety —
indicates that there is considerable structural space to explore by
varying the type and length of the linker. The optimal structure
will have to strike the appropriate balance between solubility,
pharmacokinetics, and potency. Second, the demonstration that
increases in the kon of the inhibitor driven by the cholesterol moiety
can be successfully combined with decreased inhibitor koff driven
by improved protein-protein interactions, opens the possibility to
independently optimize the two parameters and then combine
them, as we did for the VIKI mutant. Future studies will also
address the mechanism whereby the cholesterol tagged peptide
crosses the blood-brain barrier. This mechanism is currently
unknown and of great interest, with implications for treatment of
CNS diseases caused by enveloped viruses, for example the CNS
manifestations of HIV infection [76]. Current peptide antivirals
(e.g. enfuvirtide) fail to cross the blood-brain barrier [77,78], and
this has impaired the treatment of CNS diseases. Design of
peptides that can cross into the CNS could provide better
therapeutics.
Finally, since cholesterol tagging drives peptide insertion in the
target cell membrane, it may be applicable also to viruses that fuse
in the cell interior: the peptide may be carried into the cell along
with the entering virus, and exert its inhibitory action intracellu-
Figure 9. HPIV3 F HRC cholesterol-tagged peptides capture fusion intermediates of native F before fusion peptide insertion in the
target membrane. Monolayers of cells co-expressing HN and F were allowed to bind to receptor-bearing RBCs at 4uC. Upon transfer to 15uC, media
containing (A) no peptide, (B) 1 uM untagged peptide, (C) 1 uM VIKI-untagged peptide, (D) 1 uM V-chol peptide, (E) 1 uM V-PEG4-chol peptide, or (F) 1
uM VIKI-PEG4-chol peptide were added. Zanamivir was added to block HN-receptor interaction at the indicated timepoints and RBCs that were
reversibly bound by HN-receptor interaction (yellow), irreversibly bound (green), or fused (blue) were quantified. The ordinate values are means (6
SD) of results from triplicate samples.
doi:10.1371/journal.ppat.1001168.g009
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larly. Fusion inhibitors for such viruses, including influenza, have
been viewed as unlikely because the influenza fusion protein (HA)
acts only once it is sequestered in an intracellular compartment.
However lipid- tagged peptides may accompany the HA from the
cell surface to the site of fusion activation, and we have obtained
preliminary evidence for this antiviral mechanism.
Materials and Methods
Chemicals
4-guanadino-DANA (zanamivir) (I) was prepared from Relenza
Rotadisks (5 mg zanamivir with lactose). A 50 mM stock solution
was prepared by dissolving each 5 mg blister capsule in 285 mL
serum-free medium. Stock solutions were stored at 220uC.
Plasmids and reagents
The genes of NiV wt G and wt F were codon optimized and
synthesized by GeneArt (Germany) and subcloned into the
mammalian expression vector pCAGGS using EcoRI or XhoI
and BglII.
Peptide synthesis
All peptides were produced by standard Fmoc-solid phase
methods. The cholesterol moiety was attached to the peptide via
chemoselective reaction between the thiol group of an extra
cysteine residue, added C-terminally to the sequence, and a
bromoacetyl derivative of cholesterol, as previously described
[43,51,52].
Protein expression and purification
Substitutions were introduced into the homotypic and chimeric
N42(L6)C32 constructs [48] using the method of Kunkel [79] and
verified by DNA sequencing. All recombinant proteins were
expressed in E. coli BL21(DE3)/pLysS (Novagen). Cells were lysed
by glacial acetic acid and centrifuged to separate the soluble
fraction from inclusion bodies. The soluble fraction containing
protein was subsequently dialyzed into 5% acetic acid overnight at
4uC. All proteins were purified to homogeneity by reverse-phase
HPLC (Waters, Inc) on a Vydac C18 preparative column
(Hesperia, CA) using a water–acetonitrile gradient in the presence
of 0.1% trifluoroacetic acid and lyophilized. Protein identities were
confirmed by electrospray mass spectrometry (PerSeptive Biosys-
Figure 10. Biodistribution of sequence-optimized, cholesterol-
tagged peptide: Central Nervous System penetration. Golden
hamsters were injected with 2 mg/kg of VIKI -PEG4-chol peptide
subcutaneously (s.q.) At indicated times (x-axis) the animals (three for
each data point) were sacrificed, and the peptide concentrations in
plasma (panel A), or in lung, endothelium and brain (panel B) were
quantitated. The ordinate values are means (6 SD) of results from three
animals.
doi:10.1371/journal.ppat.1001168.g010
Figure 11. In vivo efficacy of sequence-optimized, cholesterol-tagged peptide. VIKI -PEG4-chol peptide injections were given to groups of 5
hamsters at 1 or 2 days before infection, concurrently with live NiV infection (day 0), and at 1, 2 or 4 days after infection. Injections were then
repeated every day for up to 14 days post infection. Control animals were injected with vehicle alone.
doi:10.1371/journal.ppat.1001168.g011
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tems Voyager Elite, Cambridge, MA). Protein concentrations were
determined by using the method of Edelhoch [80].
Crystallization and structure determination
HPLC-purified N42NiV/HeV(L6)C32HPIV3 was crystallized at
room temperature using the hanging-drop vapor diffusion method
by equilibrating against reservoir buffer (35% t-butanol, 0.1 M
sodium citrate, pH 5.6), a solution containing 1 ml of 15 mg/mL
protein dissolved in water and 1 ml of reservoir buffer. Crystals
belong to space group P212121 (a = 32.4 A˚, b = 54.1 A˚, c = 134.1
A˚) and contain three monomers in the asymmetric unit, with a
solvent content of 43.5% (Table 1). The crystals were harvested in
40% t-butanol, 0.1 M sodium citrate, pH 5.6, 15% glycerol and
frozen in liquid nitrogen. Diffraction data were recorded at 100 K
on a MAR M165 CCD detector at the beamline X4C of the
National Synchrotron Light Source at Brookhaven National
Laboratory. The images were indexed and integrated using a
monoclinic unit cell with the program DENZO [81]. The
intensities were scaled in P212121 symmetry with the program
SCALEPACK [81]; the systematic absence of intensities indicates
three 2-fold screw axes. Initial phases were determined by
molecular replacement with the program Phaser [82] by using
the structure of the monomeric HeV two-helix (PDB entry 1WP8)
as a starting model. Three N42/C32 molecules were oriented and
placed in the asymmetric unit with a Z score of 21.4 and a final
refined LLG of 669. In order to remove model bias, this model
and the dataset for N42NiV/HeV(L6)C32HPIV3 were directly fed to
the program Arp/Warp [83], which allowed ,81% of the final
model to be automatically traced. The resulting electron density
map was of excellent quality and showed the location of most of
the side chains. The linker region of chain B was built into the
evident electron density and the linker regions of chains A and C
are not visible in the electron density maps and therefore must be
disordered. Density interpretation and manual model building
were done with the program O [84]. Crystallographic refinement
of this model was carried out by using Refmac [85], resulting in
the Rfree of 29.2% and the Rwork of 23.3% between 67.1 and 1.80
A˚ resolution. At this stage, one citrate ion, two t-butanol molecules
and 156 water molecules were modeled in the electron density.
Refinement was concluded using Refmac [85] with TLS groups
assigned for each N42 or C32 monomer [86]. The final model
(Rcryst = 19.4% and Rfree = 24.2% for the resolution range 67.1–
1.80 A˚) consists of residues 3–42 and 48–80 (monomer A), 2–80
(monomer B) and 1–39 and 50–80 (monomer C), one citrate ion,
two t-butanol molecules and 156 water molecules in the
asymmetric unit. Bond lengths and bond angles of the model
have rms deviations from ideality of 0.011 A˚ and 1.2u, respectively.
The rms deviations were calculated with LSQKAB in CCP4i
program suite [87].
Circular dichroism spectroscopy
CD experiments were performed on an Aviv 62A/DS (Aviv
Associates, Lakewood, NJ) spectropolarimeter equipped with a
thermoelectric temperature control in TBS (50 mM Tris-HCl,
pH 8.0, 150 mM NaCl) and 50 uM protein. CD spectra were
collected from 260 to 200 nm at 4uC by using an average time of
5 s, a cell pathlength of 0.1 cm and a bandwidth of 1 nm. A [
theta]222 value of –35,000 deg cm
2 dmol21 was taken to
correspond to 100% helix [88]. Thermal stability was determined
by monitoring [theta]222 as a function of temperature in TBS
(pH 8.0) and with the addition of 3 or 5 M guanidine
hydrochloride (GuHCl) to facilitate unfolding. Thermal melts
were performed in two-degree intervals with a 2-min equilibration
at the desired temperature and an integration time of 30 s.
Reversibility was verified by repeated scans. Superimposable
folding and unfolding curves were observed, and .85% of the
signal was regained upon cooling. Values of midpoint unfolding
transitions (Tm) were estimated by evaluating the maximum of the
first derivative of [q]222 versus temperature data [89].
Sedimentation equilibrium analysis
Analytical ultracentrifugation measurements were carried out
on a Beckman XL-A (Beckman Coulter) analytical ultracentrifuge
equipped with an An-60 Ti rotor (Beckman Coulter) at 20uC.
Protein samples were dialyzed overnight against TBS (pH 8.0),
loaded at initial concentrations of 30, 90 and 300 uM, and
analyzed at rotor speeds of 19 and 22 krpm. Data were acquired at
two wavelengths per rotor speed setting and processed simulta-
neously with a nonlinear least squares fitting routine [90]. Solvent
density and protein partial specific volume were calculated
according to solvent and protein composition, respectively [91].
Apparent molecular masses were all within 10% of those
calculated for an ideal trimer, with no systematic deviation of
the residuals.
Transient expression of G and F genes
Transfections were performed according to the Lipofectamine
2000 manufacturer’s protocols (Invitrogen).
Cells and viruses
293T (human kidney epithelial), Vero (African green monkey
kidney cells) and CV1 cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) (Mediatech; Cellgro) supplemented with
10% fetal bovine serum and antibiotics in 5% CO2. The effect of
peptides on HPIV3 plaque number was assessed by a plaque
reduction assay performed as described previously [92]. Briefly,
CV-1 cell monolayers were inoculated with 100–200 PFU of
HPIV3 in the presence of various concentrations of peptides. After
90 minutes, 2X minimal essential medium containing 10% FBS
was mixed with 1% methylcellulose (or avicell) and added to the
dishes. The plates were then incubated at 37uC for 24 hours. After
removing the medium overlay, the cells were immunostained for
plaque detection. The number of plaques in the control (no
peptide, scrambled peptide) and experimental wells were counted
under a dissecting stereoscope.
Human airway epithelial (HAE) cultures
The EpiAirway AIR-100 system (MatTek Corporation) consists
of normal human-derived tracheo/bronchial epithelial cells that
have been cultured to form a pseudo-stratified, highly differenti-
ated mucociliary epithelium closely resembling that of epithelial
tissue in vivo. Upon receipt from the manufacturer, HAE cultures
were transferred to 6-well plates (containing 0.9 ml medium per
well) — with the apical surface remaining exposed to air — and
incubated at 37uC in 5% CO2 overnight.
Infection and treatment of HAE and measurement of viral
titers from infected HAE
HAE cultures were infected by applying 200 ul of EpiAirway
medium containing 4000 pfu of wt HPIV3 to the apical surface for
90 min at 37uC. At 90 minutes, the medium containing the
inoculum was removed, cultures were placed at 37uC and fed each
day via the basolateral surface with 0.9 ml medium. Viruses were
harvested by adding 200 ul medium per well to the HAE cultures’
apical surface and allowed to equilibrate for 30 min at 37uC. The
suspension was then collected and viral titers were determined as
previously described [53]. This viral collection was performed
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sequentially on the same wells of cells on each day post-infection.
Treatments were performed by adding medium containing 1 uM
of the indicated peptide at the time of infection only. Harvesting
by the apical surface washes was done sequentially on the same
HAE cultures, at the indicated time points.
Pseudotyped virus infection assay
The VSV-DG-RFP is a recombinant VSV derived from the
cDNA of VSV Indiana, in which the G gene is replaced with the
Ds-Red (RFP) gene. Pseudotypes with NiV G and F were
generated as described [93,94]. Briefly, 293T cells were transfect-
ed with plasmids encoding either NiV G/F. Twenty-four hours
post-transfection, the dishes were washed and infected (m.o.i. of 1)
with VSV-DG-RFP complemented with VSV G. Supernatant
fluids containing pseudotyped virus NiV G/F were collected
24 hrs post-infection and stored at 280uC. For infection assays,
NiV G/F pseudotyped viruses were used at an m.o.i. of 0.25 to
infect 293T cells. Peptides were added at various concentrations.
RFP production was analyzed by FACS (Benton Dickinson
FACSCalibur) [42,48].
Beta-galactosidase complementation-based fusion assay
We adapted an assay [95] that detects early stages of fusion
activation, since the read-out does not depend upon downstream
transactivation events. We used this assay for experiments in which
the greater range of detection of this assay was necessary. The assay
is based on alpha complementation of beta-gal; the beta-gal protein
lacking the N-terminal 85 residues (omega peptide) is expressed
from one plasmid, and the N-terminal 85 residues (alpha peptide) is
expressed from a second plasmid. Cell fusion leads to complemen-
tation, and beta-galactosidase is quantitated using the Galacto-Star
(Applied Biosystems) chemiluminescent reporter gene assay system.
Receptor bearing cells expressing the omega peptide are mixed with
viral glycoproteins co-expressing cells that also express the alpha
peptide, at various temperatures and at specific time points. Fusion
is stopped by lysing the cells with lysis buffer.
Assays for F-activation, receptor retention and receptor
release
Monolayers of 293T cells transiently expressing F-csm and
mutant HN T193A were washed three times and incubated with
1% RBC suspensions at pH 7.5 for 30 min at 4uC. After rinsing to
remove unbound RBCs, 1uM of peptide was added, the plates
were placed at the 37uC for the indicated time, zanamivir at a final
concentration of 10 mM was added and the plates left at 37uC
until the end of the latest time point (60minutes), plates then were
rocked and the liquid phase was collected in V-bottomed tubes for
measurement of released RBCs. The monolayers were then
incubated at 4uC with 200 mL of RBC lysis solution; lysis of
unfused RBCs with NH4Cl removes the RBCs whose membranes
have not fused with HN/F co-expressing cells. The liquid phase
was collected in V-bottomed 96-well plates for measurement of
reversibly bound RBCs. The cells were then lysed in 200 mL 0.2%
Triton X-100/PBS and were transferred to flat-bottom 96 well
plates for quantification of the pool of fused RBCs. The amount of
RBCs in each of the above three compartments was determined
by measurement of absorption at 410 nm.
Biodistribution analysis
15 male Syrian Golden hamsters were obtained from a
commercial source and housed in an AAALAC-approved facility
until dosing. The animals were dosed subcutaneously with
2 mg/kg of peptide dissolved in PBS. At the indicated time
points, blood was collected by cardiac puncture into chilled, Na-
heparin tubes, the plasma was separated by centrifugation, snap
frozen, and stored at 280uC until analysis. Brain, lung, and
endothelial (aorta and vena cava) tissues were also collected,
homogenized in 1 ml of PBS per gram of tissue and frozen.
Analytical samples in plasma or tissue homogenate were
prepared by precipitation of proteins with three volumes of
acetonitrile and 10% formic acid. After centrifugation, the
supernatant was analyzed by LC/MS/MS using a C18 reverse
phase HPLC column and an acetonitrile-water gradient system.
Peaks were analyzed by mass spectrometry (MS) using ESI
ionization in MRM mode. A calibration curve was prepared from
50-fold dilution of PBS peptide solutions into plasma or tissue
homogenate, as appropriate, processed as above.
Ethics statement
All work with live Nipah virus was performed in the BSL-4
laboratory of the NIAID/Rocky Mountain Laboratories (RML).
All research involving animals was conducted in strict accordance
with Animal Care and Use guidelines of the National Institutes of
Health. The protocol was approved by the Animal Care and Use
Committee at RML (National Institutes of Health Animal Study
Proposal #2009-52), approved at NIAID/RML on 5/28/2009
and at Weill Cornell on 9/14/2009. Animal work was performed
by certified staff in an Association for Assessment and Accredi-
tation of Laboratory Animal Care (AAALAC) approved facility,
and all efforts were made to minimize suffering.
Golden hamster infection
Female Syrian hamsters (6-week-old from Harlan Laboratories)
were anesthetized by chamber induction (5 Litres/min 100% O2
and 3–5% isoflurane). Each hamster was intraperitoneally (IP)
inoculated with 1000 LD50 of NiV in a 200 ul volume. For peptide
treatment, groups of 5 hamsters were treated with 2 mg/kg
peptide in a 100 ul volume by IP injection daily under isoflurane
anesthesia as described above. Treatment started on days -2, 0, 2
or 4 post infection and were continued up to 14 days post
infection. All animals were weighed daily and observed for clinical
signs. Animals were euthanized when severe neurological
symptoms were observed or when a .20% weight loss was
determined. All animals were housed under sterile conditions
using individually ventilated cages.
Supporting Information
Figure S1 HPIV3 F HRC C-terminally cholesterol-tagged
peptides interact with uncleaved F: the peptide-F interaction
attaches HN/F-expressing cells to receptor-bearing target cells.
Monolayers of cells co-expressing HN and uncleaved (cleavage site
mutant, csm) F were allowed to bind to receptor-bearing RBCs at
4uC. Upon transfer to 37uC, media containing 1 uM of the
indicated peptides were added. Zanamivir was added to block
HN-receptor interaction, and the irreversibly bound RBCs were
quantified. The ordinate values are means (6 SD) of results from
triplicate samples.
Found at: doi:10.1371/journal.ppat.1001168.s001 (4.13 MB TIF)
Figure S2 Receptor-bearing target cells bearing HPIV3 F HRC
C-terminally cholesterol-tagged peptides capture HN/F-expressing
cells via peptide-F interaction. Receptor-bearing RBCs or cells co-
expressing HN and uncleaved (csm) F were incubated with the
indicated peptides for 1 hour at RT, and washed. Binding between
RBCs and HN/F-expressing cells was allowed at 4uC. Unbound
RBCs were washed away and the cells transferred to 37uC for one
hour. Zanamivir was added to block HN-receptor interaction, and
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the irreversibly bound RBCs were quantified. The ordinate values
are means (6 SD) of results from triplicate samples.
Found at: doi:10.1371/journal.ppat.1001168.s002 (7.34 MB TIF)
Table S1 Viral titer collected from the apical surface of HAE
cells infected with wt HPIV3, in the presence of the indicated
treatments.
Found at: doi:10.1371/journal.ppat.1001168.s003 (0.05 MB PDF)
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